MDM2 promotes p21^{waf1/cip1} proteasomal turnover independently of ubiquitylation

Yetao Jin, Hunjoo Lee, Shelya X.Zeng, Mu-Shui Dai and Hua Lu¹

Department of Biochemistry and Molecular Biology, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA

¹Corresponding author
e-mail: luh@ohsu.edu

The CDK inhibitor p21^{waf1/cip1} is degraded by a ubiquitin-independent proteolytic pathway. Here, we show that MDM2 mediates this degradation process. Overexpression of wild-type or ring finger-deleted, but not nuclear localization signal (NLS)-deleted, MDM2 decreased p21^{waf1/cip1} levels without ubiquitylating this protein and affecting its mRNA level in p53^{-/-} cells. This decrease was reversed by the proteasome inhibitors MG132 and lactacystin, by p19^{arf}, and by small interfering RNA (siRNA) against MDM2. p21^{waf1/cip1} bound to MDM2 *in vitro* and in cells. The p21^{waf1/cip1}-binding-defective mutant of MDM2 was unable to degrade p21^{waf1/cip1}. MDM2 shortened the half-life of both exogenous and endogenous p21^{waf1/cip1} by 50% and led to the degradation of its lysine-free mutant. Consequently, MDM2 suppressed p21^{waf1/cip1}-induced cell growth arrest of human p53^{-/-} and p53^{-/-}/Rb^{-/-} cells. These results demonstrate that MDM2 directly inhibits p21^{waf1/cip1} function by reducing p21^{waf1/cip1} stability in a ubiquitin-independent fashion.

Keywords: MDM2/p21^{waf1/cip1}/proteasome/stability/ubiquitin

Introduction

Proteolysis plays a crucial role in regulating the pathway of the tumor suppressor p53. At least three proteins in this pathway are regulated through proteasome-mediated mechanisms. One of them is p53 itself. The nuclear p53 transcriptional activator is degraded through a ubiquitin-dependent proteasomal system mediated by an E3 ubiquitin ligase called MDM2 (Haupt *et al.*, 1997; Honda *et al.*, 1997; Kubbutat *et al.*, 1997; Fuchs *et al.*, 1998). Thus the level of p53 in a normal cell is extremely low. In response to various cellular stresses, p53 is chemically modified through processes such as phosphorylation or acetylation at its N- and/or C-terminal domains (Appella and Anderson, 2001; and references therein). Some of these modifications shield p53 from attack by MDM2 and also enhance its activity (Gu and Roeder, 1997; Shieh *et al.*, 1997; Canman *et al.*, 1998; Giaccia and Kastan, 1998; Keller *et al.*, 2001). p53 becomes stabilized and activated to induce the transcription of many target genes whose protein products either initiate apoptosis or cause cell growth arrest (Crook *et al.*,

1994; Vogelstein *et al.*, 2000). One of these p53 targets is MDM2 that in turn serves as a negative feedback regulator (Barak *et al.*, 1993; Wu *et al.*, 1993) and finely tunes p53 activity (Momand *et al.*, 1992). Besides ubiquitylating p53 and mediating its degradation, MDM2 itself is also regulated by the ubiquitin-dependent proteasome (Michael and Oren, 2003).

The third protein in the p53 pathway, which is also regulated through a proteolytic mechanism (Blagosklonny *et al.*, 1996; Maki and Howley, 1997; Fukuchi *et al.*, 1999; Nakanishi *et al.*, 2000; Sheaff *et al.*, 2000), is the cyclin-dependent kinase (CDK) inhibitor p21^{waf1/cip1} (el-Deiry *et al.*, 1993; Harper *et al.*, 1993; Bunz *et al.*, 1998). p21^{waf1/cip1} is one of the prime transcriptional targets of p53 and mediates p53-dependent cell growth arrest and senescence. Unlike p53 and MDM2, which are degraded in either the nucleus or cytoplasm (Yu *et al.*, 2000), p21^{waf1/cip1} appears to be degraded solely in the nucleus (Sheaff *et al.*, 2000). Also different from p53 and MDM2, the proteasomal turnover of p21^{waf1/cip1} is independent of its ubiquitylation (Sheaff *et al.*, 2000), although this protein can be stabilized by proteasome inhibitors and is ubiquitylated in cells (Blagosklonny *et al.*, 1996; Maki and Howley, 1997; Fukuchi *et al.*, 1999; Nakanishi *et al.*, 2000; Sheaff *et al.*, 2000). These studies suggest that ubiquitylation may not necessarily be a prerequisite for proteolysis of some protein targets by the proteasome pathway. Although it was shown recently that the 20S proteasome binds to p21^{waf1/cip1} and leads to its degradation *in vitro* (Touitou *et al.*, 2001), it is still unknown what may regulate p21^{waf1/cip1} degradation in cells. This study as described here reveals our new finding that MDM2 mediates the proteasomal turnover of p21^{waf1/cip1} without ubiquitylating this protein in cells.

Results

The level of p21^{waf1/cip1} is inversely proportional to that of MDM2 independent of p53

In our attempt to identify the regulator of p21^{waf1/cip1} stability, we tested whether MDM2 is involved in modulating the p21^{waf1/cip1} level in cells, because both MDM2 and p21^{waf1/cip1} are always induced by p53 whenever p53 is activated (Vogelstein *et al.*, 2000). Thus, MDM2 would have the chance to target p21^{waf1/cip1} for degradation. Also, when examining the level of p21^{waf1/cip1} in MDM2-deficient or proficient cell lines, we found that its level is inversely proportional to that of MDM2 (Figure 1). p21^{waf1/cip1} protein was low in p53^{-/-} mouse embryonic fibroblast (MEFs), but was markedly elevated in p53^{-/-}/mdm2^{-/-} MEFs (Figure 1A). This alteration was not due to the elevation of its mRNA

Fig. 1. The deficiency of MDM2 in p53-null cells increases the p21^{waf1/cip1} level. (A) The level of p21^{waf1/cip1} protein, but not mRNA, increased in p53^{-/-}/mdm2^{-/-} MEFs. p53^{-/-} or p53^{-/-}/mdm2^{-/-} MEFs were treated with either MG132 (1 μM) or DMSO. At 6 h after treatment, cells were harvested. Cell lysates (100 μg proteins) were loaded directly onto an SDS-gel. Proteins were detected by WB using antibodies as indicated on the right. The level of GAPDH or p21^{waf1/cip1} mRNA was detected by RT-PCR. F9 cells containing wild-type p53 were irradiated with 7 Gy of γ-irradiation (F9γ) and harvested 1 h post-irradiation as a positive control for RT-PCR with p21^{waf1/cip1} primers. F9 denotes non-irradiated F9 cells. The numbers 3 and 1 indicate the fold induction. (B) The proteasome inhibitor lactacystin also restores the level of p21^{waf1/cip1} in p53^{-/-} MEFs. Lactacystin (10 μM) was used as indicated on the top. Cell lysates (75 μg) were loaded directly on an SDS-gel for WB using antibodies as indicated on the right. (C) MDM2 decreases the level of endogenous p21^{waf1/cip1}. p53^{-/-}/mdm2^{-/-} MEFs were transfected with pCDNA3 or pCDNA3-HA-MDM2 (1X = 1 μg) and harvested 48 h after transfection. Cell lysates (100 μg of proteins) were used for WB using antibodies as indicated on the right.

level (Figure 1A). Interestingly, MG132 (Figure 1A) or lactacystin (Figure 1B) treatment only restored the level of p21^{waf1/cip1} in p53^{-/-} MEFs, but not that in p53^{-/-}/mdm2^{-/-} MEFs, suggesting that the protein level of p21^{waf1/cip1} is regulated by MDM2. Thus, blocking the proteasome pathway may not be necessary for stabilizing p21^{waf1/cip1} in the absence of MDM2. Also, the increase of p21^{waf1/cip1} in these p53^{-/-}/mdm2^{-/-} cells was independent of p53. Consistently, ectopic expression of MDM2 in p53^{-/-}/mdm2^{-/-} MEFs markedly decreased endogenous p21^{waf1/cip1} (Figure 1C). These results suggest that MDM2 may be involved in regulating the proteasomal turnover of p21^{waf1/cip1} in cells.

MDM2 does not require its ring finger to mediate p21^{waf1/cip1} degradation in the nucleus

To test this possibility, we first checked whether overexpression of MDM2 leads to a decrease of p21^{waf1/cip1} level by comparing wild-type MDM2 with its deletion mutants. Human p53-null lung adenocarcinoma H1299 cells were transfected with plasmids encoding p21^{waf1/cip1} alone or together with wild-type and deletion mutant MDM2s. At 48 h after transfection, cells were harvested for western blot (WB) and northern blot (NB) analyses. In line with the results in Figure 1, overexpression of MDM2 reduced the protein, but not the mRNA, level of p21^{waf1/cip1} (Figure 2B). Surprisingly, this reduction did not appear to absolutely require the C-terminal ring finger domain of MDM2, as the 1–441 MDM2 mutant that was unable to mediate p53 degradation (Figure 2D) also reduced p21^{waf1/cip1} (Figure 2B). However, the nuclear localization signal (NLS) domain of MDM2 seems to be critical as p21^{waf1/cip1} levels did not change in the presence of the ΔNLS (Δ150–230) MDM2 mutant (Figure 2B). In contrast, this mutant was still able to lead to p53 degradation (Figure 2D). Remarkably, MG132 treatment reversed the reduction of p21^{waf1/cip1} by both the wild-type and 1–441 mutant MDM2s (Figure 2C). The N-terminal p53-binding domain of MDM2 was also dispensable for decreasing p21^{waf1/cip1} (data not shown). Furthermore, wild-type and 1–441 MDM2s localized in the nucleus, whereas the Δ150–230 MDM2 stayed in the cytoplasm (Figure 2E). Additionally, MDM2 reduced the level of p21^{waf1/cip1} in the presence of the nuclear export inhibitor leptomycin B (LMB) in H1299 cells (Figure 2F). LMB blocks the nuclear export of MDM2 (Freeman and Levine, 1998; and our unpublished data). These results suggest that MDM2 may mediate the degradation of both exogenous and endogenous p21^{waf1/cip1} independently of its E3 ubiquitin ligase domain in the nucleus.

MDM2 does not mediate p21^{waf1/cip1} ubiquitylation in cells

The observation that the ring finger domain of MDM2 was dispensable for the MDM2-mediated p21^{waf1/cip1} decrease (Figure 2) suggests that MDM2 might not ubiquitylate p21^{waf1/cip1}. To test this possibility, p53-null H1299 cells and p53^{-/-}/mdm2^{-/-} MEFs were transfected with vectors encoding p21^{waf1/cip1}, His₆-ubiquitin and hemagglutinin (HA)-MDM2 in different combinations. Ubiquitylated MDM2 or p21^{waf1/cip1} molecules were pulled-down by Ni-NTA-agarose and probed with anti-MDM2 or anti-p21^{waf1/cip1} antibodies. Consistent with the results in Figure 2, MDM2 did not ubiquitylate p21^{waf1/cip1}, though p21^{waf1/cip1} was ubiquitylated in these cells (Figure 3A and B) as expected (Maki and Howley, 1997; Fukuchi *et al.*, 1999; Sheaff *et al.*, 2000). p21^{waf1/cip1} ubiquitylation must be catalyzed by an unknown E3 ubiquitin ligase, as p21^{waf1/cip1} ubiquitylation was detected in MEFs that do not have the *mdm2* gene (Figure 3A). In contrast, exogenous MDM2 was ubiquitylated efficiently in both cell lines (Figure 3A and B). The reduction of p21^{waf1/cip1} or MDM2 ubiquitylation when the two proteins were co-expressed might be due to the competition of these proteins for the limited pool of His₆-tagged ubiquitins (Figure 3A and B). Alternatively, p21^{waf1/cip1} may also inversely regulate the MDM2 level, though this idea needs

Fig. 2. Wild-type and 1-441 MDM2, but not Δ150-230 MDM2, lead to a decrease in the p21^{waf1/cip1} protein level in p53-null cells. **(A)** Schematic presentation of functional domains of MDM2 and its deletion mutants. NLS and NES stand for nuclear localization and export signals, respectively. Numbers denote amino acids. **(B)** Overexpression of wild-type and 1-441 MDM2 reduces p21^{waf1/cip1} in cells. H1299 cells were transfected with plasmids encoding p21^{waf1/cip1} (1 μg), HA-MDM2 (1x = 1 μg, 2x = 2 μg), 1-441 MDM2 (2 μg) and Δ150-230 MDM2 (2 μg) as indicated on the top. Cell lysates (100 μg of proteins) were loaded onto an SDS-gel for WB using antibodies as indicated on the left. A 15 μg aliquot of total RNA was used for NB (two bottom panels). **(C)** Proteasomal inhibitor MG132 blocks MDM2-mediated p21 degradation. A transfection assay was carried out as in (B) except that the transfected cells were treated with MG132 (10 μM) for 6 h prior to harvesting. **(D)** Degradation of p53 requires an intact MDM2 ring finger domain. A control transfection was done similarly to (B) except that p53 was used as a substrate. **(E)** Wild-type and 1-441 MDM2 proteins localized in the nucleus while the Δ150-230 MDM2 localized in the cytoplasm. Immunofluorescent staining of p21^{waf1/cip1} and MDM2 was conducted 48 h after transfection as described in (B). Antibodies used in this experiment are indicated on the top. Arrows show the expressed p21^{waf1/cip1} or MDM2 proteins in cells. **(F)** MDM2 decreases p21^{waf1/cip1} in the presence of LMB. H1299 cells were transfected with the p21^{waf1/cip1} plasmid with pCDNA3 or pCDNA3-HA-MDM2 (1 μg each). After 24 h, transfected cells were incubated with 15 ng/ml of LMB and harvested overnight after treatment. Cell lysates (100 μg of proteins) were used for WB using antibodies as indicated on the left.

to be clarified. Nevertheless, these results clearly show that MDM2 does not ubiquitylate p21^{waf1/cip1} in cells. Consistent with this notion, overexpression of MDM2 as well as its ring finger-truncated mutant also led to

degradation of a p21^{waf1/cip1} mutant with six lysine-arginine (6KR) substitutions (Figures 3C and 5A). The p21^{waf1/cip1} 6KR mutant was shown to be degraded as efficiently as wild-type p21^{waf1/cip1} in cells, though the

Fig. 3. MDM2 does not ubiquitylate p21^{waf1/cip1} in cells. (A) *p53*^{-/-}/*mdm2*^{-/-} MEFs were transfected as described in Figure 2A, except that His₆-ubiquitin (His-Ub) was used along with p21^{waf1/cip1} and/or HA-MDM2. Cells were treated with 10 μM MG132 for 6 h prior to being harvested. Cell lysates (350 μg) were incubated with Ni-NTA beads. Beads were washed intensively prior to being loaded onto an SDS-gel for WB using antibodies against p21^{waf1/cip1} or MDM2. A 100 μg aliquot of proteins in lysates was used to show input levels. (B) MDM2 does not ubiquitylate p21^{waf1/cip1} in H1299 cells. The same assay was conducted as described in (A) except that H1299 cells were used. The p21^{waf1/cip1} mutant containing six lysine substitutions with arginines (6KR) (Figure 5A) was used as a negative control for ubiquitylation. The asterisk denotes non-specific signals that were pulled-down by Ni-NTA beads. (C) MDM2 decreases the p21^{waf1/cip1} 6KR mutant in cells. The same transfection as that in Figure 2A was conducted, except that the p21^{waf1/cip1} 6KR mutant was used. A 50 μg aliquot of cell lysates was used for WB with antibodies as indicated on the left.

mutant was not ubiquitylated in cells (Figure 3B; Sheaff *et al.*, 2000). These results demonstrate that MDM2 does not ubiquitylate p21^{waf1/cip1} in cells.

MDM2 reduces the half-life of both exogenous and endogenous p21^{waf1/cip1}

Next we wanted to determine whether MDM2 truly affects the turnover of p21^{waf1/cip1} by performing pulse-chase experiments using [³⁵S]methionine. As shown in Figure 4A, MDM2 markedly reduced the half-life of p21^{waf1/cip1} from ~2 h to ~45 min in H1299 cells (Figure 4A). Similarly, 1–441 MDM2 also reduced the half-life of p21^{waf1/cip1}, though to a lesser extent (Figure 4A). Again, the total level of p21^{waf1/cip1} drastically decreased in the presence of wild-type or 1–441 mutant MDM2 (lower panels of Figure 4A). In agreement with these results, the half-life of endogenous p21^{waf1/cip1} was also shortened to ~30 min from ~100 min when MDM2 was expressed in *p53*^{-/-}/*mdm2*^{-/-} MEFs (Figure 4B). These results demonstrate that MDM2 accelerates the turnover of p21^{waf1/cip1} in cells.

MDM2 binds to the C-terminal half of p21^{waf1/cip1} *in vitro*

Then, we determined whether MDM2 interacts with p21^{waf1/cip1} by performing a set of GST–protein interaction assays. Purified GST–p21 (Figure 5A) or GST–MDM2 (Figure 5C) were incubated with either His₆-MDM2 or His₆-p21 purified from bacteria. As shown in Figure 5, MDM2 physically bound to p21^{waf1/cip1} as well as its C-terminal domain half (Figure 5B). Interestingly, p21^{waf1/cip1} appeared to bind preferentially to the MDM2 central region (amino acids 222–425) that contains a zinc finger domain (amino acids 290–390), because neither the N-terminal domain (amino acids 1–150) nor the C-terminal domain (amino acids 425–491) was able to bind to the p21^{waf1/cip1} protein as well as did wild-type MDM2 or the 285–384 region (Figure 5C). The central p21^{waf1/cip1}-binding domain (amino acids 222–437) of MDM2 is crucial for MDM2-mediated p21^{waf1/cip1} degradation, as deletion of this domain rendered the MDM2 mutant unable to degrade p21^{waf1/cip1} in cells (Figure 5D), even though both this mutant and p21^{waf1/cip1} were in the nucleus (data not shown). These results demonstrate that MDM2 physically associates with p21^{waf1/cip1} *in vitro* and this association is crucial for MDM2 to degrade p21^{waf1/cip1} in cells.

MDM2 binds to p21^{waf1/cip1} in cells

In order to determine whether endogenous MDM2 and p21^{waf1/cip1} proteins indeed associate with each other in cells, we performed two experiments. First, we tested whether this association is detectable upon DNA damage, which induces p53 and thus MDM2 and p21^{waf1/cip1}. To do so, human astrocytoma SJSA cells that contain wild-type p53 were irradiated with 7 Gy of γ-irradiation and harvested at different time points for WB and immunoprecipitation (IP)–WB analyses. As shown in Figure 6A, both MDM2 and p21^{waf1/cip1} were induced by p53 upon irradiation (left panels). Interestingly, the endogenous MDM2 protein was co-immunoprecipitated with anti-p21^{waf1/cip1} (lane 3) or anti-MDM2 (lane 8) antibodies 4 h post-irradiation (lanes 1–3). This result was reproducible

and not non-specific, as MDM2 was not detected in the reaction with an anti-actin antibody (lanes 4–6). Secondly, we tested whether MDM2 and p21^{waf1/cip1} associate in human cervical carcinoma HeLa or SJSA cells after treatment with MG132. Indeed, this was true for both of the cell lines. As shown in Figure 6B for HeLa cells, MDM2 and p21^{waf1/cip1} were co-immunoprecipitated with anti-p21^{waf1/cip1} (lane 4) or anti-MDM2 (lane 8) antibodies but not with anti-actin antibodies (lane 6), only when the p21^{waf1/cip1} level was induced by MG132. Hence, these results using two different human cell lines demonstrate that MDM2 binds to p21^{waf1/cip1} when both of the proteins are induced.

Suppression of MDM2 induces p21^{waf1/cip1} in p53-null cells

Next, we wanted to determine whether suppressing MDM2 would induce p21^{waf1/cip1} in a p53-independent fashion by conducting two different experiments. First, because mouse p19^{arf} inhibits MDM2-mediated p53 degradation (Honda and Yasuda, 1999; Xirodimas *et al.*, 2001), we tested whether this protein also affects MDM2-mediated p21^{waf1/cip1} degradation. H1299 cells were transfected with the p21^{waf1/cip1} plasmid, and/or the MDM2 plasmid or together with the p19^{arf} plasmid.

Protein levels were detected by WB analysis 48 h after transfection. As expected, MDM2 again led to a reduction of the p21^{waf1/cip1} level, but p19^{arf} reversed this reduction (Figure 7A). It has been suggested that p19^{arf} inhibits p53 degradation by MDM2 either by moving MDM2 to the nucleolus and thus sequestering it away from p53 (Zhang *et al.*, 1998; Tao and Levine, 1999; Weber *et al.*, 1999) or through direct interaction with MDM2 (Kamijo *et al.*, 1998; Llanos *et al.*, 2001; Clark *et al.*, 2002). Thus, p19^{arf} may do the same to reverse p21^{waf1/cip1} degradation by MDM2. Indeed, in the presence of p19^{arf}, both p21^{waf1/cip1} and MDM2 were detected in the nucleolus (the bottom row of Figure 7B). MDM2 was moved to the nucleolus by p19^{arf} (second row from top), because MDM2 and/or p21^{waf1/cip1} were scattered in the nucleus in the absence of p19^{arf} (the second bottom row of Figure 7B, and Figure 2E). Consistently, these three proteins formed a ternary complex in cells (Figure 7C). This complex formation requires MDM2, as p21^{waf1/cip1} did not bind p19^{arf} in the absence of MDM2 (Figure 7D). Furthermore, being in the nucleolus appears to be critical for p19^{arf} inhibition of MDM2-mediated p21^{waf1/cip1} degradation, as p19^{arf}, which was unable to bring the 1–441 MDM2 into the nucleolus (Figure 7F; Weber *et al.*, 2000), failed to protect p21^{waf1/cip1} from degradation by this mutant

Fig. 4. MDM2 reduces the half-life of both exogenous and endogenous p21^{waf1/cip1}. (A) Pulse-chase cell labeling demonstrates that p21^{waf1/cip1} displays a decreased half-life in the presence of MDM2. H1299 cells were transfected with the p21^{waf1/cip1} (1 μ g) plasmid alone or together with plasmids encoding MDM2 (2 μ g) or 1–441 MDM2 (2 μ g). At 40 h post-transfection, the cells were incubated with [³⁵S]methionine-containing medium (400 μ Ci per 100 mm plate) for 45 min. Cells were then transferred to normal medium after washing, and harvested at 0, 15, 45, 90 and 180 min. Lysates with an isotope count of $\sim 14 \times 10^6$ c.p.m. were used for immunoprecipitation with the anti-p21^{waf1/cip1} antibody, followed by either autoradiography or WB with the anti-p21^{waf1/cip1} antibody. The intensity of the bands was quantified using Adobe Photoshop and plotted on a graph. Dashed lines indicate the half-life of p21^{waf1/cip1} in each experiment. (B) MDM2 reduces the half-life of endogenous p21^{waf1/cip1}. p53^{-/-}/mdm2^{-/-} MEFs were transfected with pCDNA3 and pCDNA3-HA-MDM2, respectively. At 40 h after transfection, cells were treated with 50 μ g/ml cycloheximide (CHX) and harvested at different time points. An 80 μ g aliquot of cell lysates was used for WB using antibodies as indicated on the left. The intensity of the p21^{waf1/cip1} bands was quantified as described in (A) and plotted on a graph.

Fig. 5. MDM2 binds to p21 *in vitro*. (A) Schematic representation of p21^{waf1/cip1} domains and deletions. The positions of six lysines are indicated. Boxes denote the protein-binding domains. (B) A GST-p21^{waf1/cip1} pull-down using purified proteins that MDM2 binds to the C-terminus of p21^{waf1/cip1} *in vitro*. The experiments were conducted as described in Materials and methods. The amounts of MDM2 used are indicated on the top of the left panel; 10% input of MDM2 is shown. The right panel shows the result using two GST-p21^{waf1/cip1} deletions as indicated in (A). Bound MDM2 is shown on the top panel, in which 10% of the input is shown on the right. The GST-p21^{waf1/cip1} proteins were analyzed by both Coomassie blue staining (lower panels) and WB using anti-p21^{waf1/cip1} antibodies (data not shown). (C) p21^{waf1/cip1} interacts with the central domain of MDM2 *in vitro*. GST-MDM2 pull-down assays were conducted with GST-WT MDM2 or deletion mutants, as indicated, and with purified His-p21^{waf1/cip1}. Bound p21^{waf1/cip1} was detected by WB using anti-p21^{waf1/cip1} antibodies; 10% of input is shown on the right. (D) The Δ222-437 mutant of MDM2 is unable to degrade p21^{waf1/cip1} in cells. H1299 cells (50% confluence) were transfected with plasmids encoding either MDM2 (2 μg) or Δ222-437 MDM2 (1X = 0.5 μg) along with the p21^{waf1/cip1} plasmid (1 μg) as indicated on the top. A 60 μg aliquot of cell lysates was used for WB with antibodies as indicated on the right.

MDM2 (Figure 7E). Finally, two oncoproteins, c-Myc and E1A, which have been shown to induce p19^{arf} (de Stanchina *et al.*, 1998; Zindy *et al.*, 1998), also induced p21^{waf1/cip1} in p53^{-/-} MEFs (Figure 7G). These results confirm that the degradation of p21^{waf1/cip1} is mediated by MDM2, which is blocked by p19^{arf} through a subcellular separation mechanism.

Secondly, we tested whether direct suppression of MDM2 by small interfering RNA (siRNA) could elevate p21^{waf1/cip1} levels. H1299 cells were transfected with two different concentrations of the anti-MDM2 siRNA oligomers or scrambled RNA oligomers as a control using Oligofectamine (Invitrogen). Cells were harvested for WB

analysis with antibodies against MDM2 or p21^{waf1/cip1}. As shown in Figure 8A, the MDM2 level was markedly reduced by the anti-MDM2 siRNA in a dose-dependent manner, but not by the scrambled RNA. Consistent with the results in Figures 1-4, the p21^{waf1/cip1} level was inversely elevated when the MDM2 level decreased (Figure 8A). As clearly depicted in the graphic presentation, 300 nM of anti-MDM2 siRNA oligomers resulted in a >2-fold induction of p21^{waf1/cip1} while reducing the level of MDM2 by >2-fold. We can rule out the possibility that p21^{waf1/cip1} was induced through activation of endogenous p73 by anti-MDM2 siRNA, as there was no detectable p73 in H1299 cells (Zeng *et al.*, 1999). Also, p73 was not

Fig. 6. (A) MDM2 binds to p21^{waf1/cip1} in cells after irradiation. SJSA cells (80% confluence) were irradiated with 7 Gy of γ -irradiation and harvested 2 and 4 h post-irradiation for WB (left panels) with antibodies against MDM2, p53 and p21^{waf1/cip1}, respectively, and IP using anti-p21^{waf1/cip1}, anti-actin, or anti-MDM2 antibodies followed by WB with antibodies against MDM2 or p21^{waf1/cip1} (right panels). The 2 h point was not included in the IP analysis with anti-MDM2 antibodies because no interaction was detected at this point with anti-p21 antibodies. (B) MDM2 binds to p21^{waf1/cip1} in cells after MG132 treatment. HeLa cells (80% confluence) were treated with 10 μ M MG132 for 16 h and harvested for WB analysis. An 80 μ g aliquot of cell lysates was used for WB (left panels) and 350 μ g of proteins were used for IP with anti-p21^{waf1/cip1}, anti-actin or anti-MDM2 antibodies, as indicated on the top, followed by WB with antibodies as indicated on the left. Numbers between the panels indicate the molecular weight markers.

induced non-specifically by the stress of siRNA transfection (data not shown). Furthermore, the p21^{waf1/cip1} induction was not due to activation of p63 either, as MDM2 was shown previously to enhance p63 activity (Calabro *et al.*, 2002; and data not shown). Thus, suppressing MDM2 would reduce p63 activity. Finally, because this cell line lacks p53, these results demonstrate that suppressing MDM2 function or reducing its expression can rescue p21^{waf1/cip1} from degradation independently of p53.

Degradation of p21^{waf1/cip1} mediated by MDM2 is independent of MDMx

A recent discovery that deletion of the p53 gene can rescue the lethal phenotype of MDMx-deficient mice (Parant *et al.*, 2001; Migliorini *et al.*, 2002;) suggests that MDMx may be in the same pathway as MDM2. To test whether the p21^{waf1/cip1} degradation mediated by MDM2 is dependent upon MDMx, we introduced p21^{waf1/cip1} alone or together with MDM2 into p53^{-/-}mdmx^{-/-} MEFs. As shown in Figure 8B and C, ectopic expression of MDM2 reduced the level of either exogenous or endogenous p21^{waf1/cip1} in the absence of MDMx. These results suggest that MDM2

can mediate p21^{waf1/cip1} degradation independently of MDMx.

MDM2 functionally reverses the cell growth suppression induced by p21^{waf1/cip1}

To determine the functional consequence of the degradation of p21^{waf1/cip1} by MDM2, fluorescence-activated cell sorting (FACS) analysis was carried out after transfection of H1299 cells with either the p21^{waf1/cip1} plasmid alone or together with the MDM2 plasmid. At 48 h after transfection and 16 h after nocodazole treatment, cells were harvested for cell sorting and cytometry. As expected, ectopic expression of p21^{waf1/cip1} in these cells induced cell growth arrest at G₁ phase (~25%) in comparison with the vector control (~7%) (Figure 9A). Overexpression of MDM2 conversely brought G₁ cells down to ~7 or ~5% even in the presence of p21^{waf1/cip1}, indicating that MDM2 directly inhibits p21^{waf1/cip1} function. Consistent with this result, MDM2 also reversed p21^{waf1/cip1}-induced suppression of cell growth in a colony formation assay using p53- and Rb-null human osteosarcoma Saos-2 cells (Figure 9B). Saos-2 cells were used to exclude the possibility that MDM2 might inhibit

p21^{waf1/cip1} function by inactivating p53 and Rb (Momand *et al.*, 1992; Xiao *et al.*, 1995). Taken together, these results demonstrate that MDM2 negatively affects p21^{waf1/cip1}-mediated cell growth arrest in a p53- or Rb-independent fashion.

Discussion

Our study identifies MDM2 as a cellular p21^{waf1/cip1} regulator that mediates its proteasomal turnover. The significance of this study is 2-fold. First, this finding adds another level of regulation to the p53 pathway. Because p21^{waf1/cip1} mediates p53-induced G₁ arrest in response to DNA damage (el-Deiry *et al.*, 1993; Harper *et al.*, 1993), MDM2 would inhibit G₁ arrest more effectively by degrading both p53 and p21^{waf1/cip1} simultaneously. Several lines of evidence support this hypothesis. First, ectopic expression of MDM2 in p53-null cells inhibited

p21^{waf1/cip1}-mediated growth arrest (Figure 9). Also the p21^{waf1/cip1} protein level, but not the mRNA level, was elevated in p53^{-/-}/mdm2^{-/-} MEFs in comparison with that in p53^{-/-} MEFs (Figure 1). Consistently, the level of p21 was inversely proportional to that of MDM2 when the MDM2 expression was suppressed by siRNA targeting in p53-null cells (Figure 8). Furthermore, ectopic expression of MDM2 resulted in the degradation of both exogenous and endogenous p21^{waf1/cip1} (Figures 1–3) as well as shortening the half-life of both exogenous and endogenous p21^{waf1/cip1} (Figure 4). Moreover, this degradation was rescued by overexpression of p19^{arf} (Figure 7). Also, overexpression of c-Myc or E1A oncoproteins, which induce p19^{arf} (de Stanchina *et al.*, 1998; Zindy *et al.*, 1998) induced p21^{waf1/cip1} in p53-null MEFs (Figure 7G). Finally, MDM2 specifically mediates p21^{waf1/cip1} degradation, as MDM2 did not affect the level of another CDK inhibitor p27 (data not shown). These results strongly demonstrate

that MDM2 regulates p21^{waf1/cip1} proteasomal turnover in cells. Hence, targeting two components of the p53 pathway by MDM2 is biologically significant.

To our surprise, the degradation of p21^{waf1/cip1} by MDM2, unlike that of p53 (Haupt *et al.*, 1997; Honda *et al.*, 1997; Kubbutat *et al.*, 1997), does not need its

Fig. 7. (A) p19^{arf} inhibits MDM2-mediated p21^{waf1/cip1} degradation. A transfection similar to that in Figure 2B was carried out, except that Myc-p19^{arf} (1x = 1 µg, 2x = 2 µg) was used. (B) p19^{arf} recruits MDM2 and p21^{waf1/cip1} into the nucleolus. H1299 cells were transfected with plasmids encoding MDM2, p21^{waf1/cip1} and p19^{arf} in different combinations as indicated on the left. At 48 h after transfection, cells were fixed for immunofluorescent staining with antibodies as indicated on the top of the panels. The nucleus was stained with DAPI. (C) p19^{arf}, MDM2 and p21^{waf1/cip1} form a ternary complex in cells after overexpression. H1299 cells were transfected with p19^{arf}, MDM2 and p21^{waf1/cip1} plasmids or with an empty vector as indicated above. A 500 µg aliquot of cell lysates was used for IP with anti-MDM2 and anti-p21^{waf1/cip1} antibodies, followed by WB with antibodies against MDM2, p21^{waf1/cip1} and p19^{arf}. (D) p21^{waf1/cip1} does not bind to p19^{arf} in cells without MDM2. The same transfection followed by IP-WB was conducted as that in (C) except MDM2 was not used. (E) p19^{arf} does not rescue p21^{waf1/cip1} degradation mediated by the Δ-Ring MDM2 mutant in cells. The same transfection was conducted as that in (C) except the Δ-Ring MDM2 mutant was used. A 60 µg aliquot of cell lysates was directly loaded to an SDS-gel for WB with antibodies against MDM2, tubulin, p21^{waf1/cip1} and p19^{arf}. (F) p19^{arf}, p21^{waf1/cip1} and Δ-Ring MDM2 are located in the nucleus. Immunofluorescent staining analysis of transfected H1299 cells with plasmids encoding Myc-p19^{arf}, p21^{waf1/cip1} or Δ-Ring MDM2 as indicated on the left. Antibodies used for this staining are indicated on the top of the corresponding panels. (G) c-Myc, E1A and p19^{arf} induce p21^{waf1/cip1} in p53^{-/-} MEFs. p53^{-/-} MEFs were transfected with plasmids encoding c-Myc, E1A or p19^{arf} and harvested for WB analysis with anti-p21^{waf1/cip1} antibodies. A 75 µg aliquot of cell lysates was used.

Fig. 8. Suppression of MDM2 expression by siRNA induces p21^{waf1/cip1} in p53-null cells. (A) SiRNA against MDM2 inhibits MDM2 expression and induces p21^{waf1/cip1} in p53-null H1299 cells. H1299 cells were transfected with a scrambled RNA oligomer as a control, and 100 and 300 nM of the anti-MDM2 siRNA oligomer duplex, and harvested 72 h post-transfection for WB with anti-MDM2, anti-p21 and anti-α-tubulin antibodies. A 100 μg aliquot of cell lysates was used for WB and the blot was exposed to X-ray film for >3 h. The intensity of the proteins was quantified with Adobe Photoshop and the data were plotted on a graph. (B and C) MDM2 degraded both exogenous and endogenous p21^{waf1/cip1} independently of MDMx. p21^{waf1/cip1} and MDM2 alone or together were introduced into p53^{-/-}/mdmx^{-/-} MEFs. A 100 μg aliquot of cell lysates was used for WB using antibodies as indicated on the left. The upper panel shows exogenous p21^{waf1/cip1} (B), while the lower panel shows endogenous p21^{waf1/cip1} (C).

intrinsic E3 ubiquitin ligase activity (Figures 2–4). Thus, this finding suggests a novel ring finger-independent mechanism for MDM2-mediated proteolysis of some target proteins such as p21^{waf1/cip1}. Although how MDM2 exactly leads to p21^{waf1/cip1} degradation still remains to be investigated, it is plausible that MDM2

Fig. 9. MDM2 rescues cell growth arrest mediated by p21^{waf1/cip1} independently of p53. (A) MDM2 inhibits p21^{waf1/cip1}-induced G₁ arrest. H1299 cells were transfected with plasmids as indicated on the top of the table and fixed for FACS analysis 40 h after transfection and 16 h after nocodazole treatment. pCEP4-MDM2 (1x = 1 μg, 2x = 2 μg of DNA) was used here. Reproducible results are presented in the graph with error bars below the table. The y-axis denotes the percentage of cells in G₁ phase. (B) MDM2 rescues p21^{waf1/cip1}-induced suppression of colony formation. Saos-2 cells were transfected with pCDNA3-p21^{waf1/cip1} in the presence or absence of pCEP4-MDM2 (1x = 1 μg, 2x = 2 μg of DNA). pCMV-MDM2 and pCDNA3 were used as controls. Cells were incubated in DMEM containing 10% FBS and 0.5 mg/ml G418. Media were changed once per 4–5 days. Colonies were stained ~4 weeks after transfection. These results were reproducible.

may recruit the 26S proteasomal machinery to degrade p21^{waf1/cip1}, as MDM2 directly interacted with this protein (Figure 5), and the proteasome inhibitor MG132 was able to rescue this degradation, subsequently increasing the level of p21^{waf1/cip1} (Figure 2). In line with this idea, some yeast E3 ligases have been shown to interact directly with the 19S complex of the 26S proteasome (Xie and Varshavsky, 2000), and mammalian p21^{waf1/cip1} could bind to the 20S complex directly (Touitou *et al.*, 2001). Thus, MDM2 might bind to the 19S complex and p21^{waf1/cip1}, recruiting

p21^{waf1/cip1} to the 20S complex. Alternatively, MDMx may serve as a partner of MDM2 in regulating p21^{waf1/cip1} stability, though MDMx is not essential for MDM2-mediated p21^{waf1/cip1} degradation (Figure 8B). It is also possible that other unknown proteins might bind to the MDM2–p21^{waf1/cip1} complex and thus serve as an adaptor to bring the 26S proteasome complex to p21^{waf1/cip1}. Though all of these hypotheses remain to be studied, it is conceivable that this event exclusively occurs in the nucleus, because (i) p21^{waf1/cip1} co-localized with MDM2 in the nucleus, and the mutant MDM2 expressed in cytoplasm, though able to degrade p53, was unable to degrade p21^{waf1/cip1} (Figure 2); and (ii) MDM2 was able to degrade p21^{waf1/cip1} even in the presence of the nuclear export inhibitor LMB (Figure 2F). This notion is in accordance with the earlier report showing that p21^{waf1/cip1} was degraded in the nucleus (Sheaff *et al.*, 2000). In addition, the MDM2–p21^{waf1/cip1} interaction was detected in p53-proficient cells after irradiation or treatment with the proteasomal inhibitor MG132 (Figure 6). Therefore, it is certain that MDM2 binds to and degrades p21^{waf1/cip1} in the nucleus. Our finding does not exclude the present concept that MDM2 degrades p53 through a ubiquitin-mediated proteasome system (Honda *et al.*, 1997; Fang *et al.*, 2000). Ubiquitin-independent proteolysis has begun to emerge as a common pathway, parallel to the ubiquitin-dependent one, for regulating the turnover of some cellular proteins (Sheaff *et al.*, 2000; Verma and Deshaies, 2000; David, 2002; Hoyt *et al.* 2003; Orlowski and Wilk, 2003). Therefore, elucidating the detailed mechanism underlying MDM2-mediated p21^{waf1/cip1} degradation would be instrumental for better understanding of this pathway.

Identification of MDM2 as a regulator of p21^{waf1/cip1} turnover may provide insight into understanding how MDM2 regulates p53-independent pathways. It has been shown that transforming growth factor- β (TGF- β) induces the expression of p21^{waf1/cip1} through a p53-independent mechanism (Datto *et al.* 1995) and that MDM2 can rescue TGF- β -induced growth arrest in a p53-independent manner (Sun *et al.* 1998). It is possible that MDM2 may inhibit TGF- β -dependent growth arrest by mediating the proteasomal degradation of p21^{waf1/cip1}. Thus further investigating the likely involvement of the MDM2-mediated p21^{waf1/cip1} turnover in the TGF- β signaling pathway would be an interesting topic for future research.

Materials and methods

Cell culture

Human lung adenocarcinoma H1299 cells, human embryonic kidney epithelial 293 cells, mouse embryonic testicular carcinoma F9 cells and mouse p53^{-/-}, p53^{-/-}/mdm2^{-/-} or p53^{-/-}/mdmx^{-/-} MEFs were cultured as previously described (Zeng *et al.*, 2000). The 293-HA-MDM2 stable cell line was established by introducing pCDNA3-HA-MDM2 into 293 cells and selecting with 0.5 mg/ml G418 for 3–4 weeks. Cell clones that expressed HA-MDM2 were confirmed by immunofluorescent staining and WB analyses with anti-HA antibodies.

Buffers

Lysis buffer consisted of 50 mM Tris–HCl pH 8.0, 0.5% NP-40, 1 mM EDTA, 150 mM NaCl and 1 mM phenylmethylsulfonyl fluoride (PMSF). Buffer C 100 (BC100) included 20 mM Tris–HCl pH 7.9, 0.1 mM EDTA, 10% glycerol, 100 mM KCl, 4 mM MgCl₂, 0.2 mM PMSF, 1 mM

dithiothreitol (DTT) and 0.25 mg/ml of pepstatin A. The 1 $\times$ SSC consisted of 0.15 M NaCl, 15 mM sodium citrate pH 7.0.

Antibodies and plasmids

Monoclonal anti-Flag and anti- α -tubulin antibodies were purchased from Sigma. The polyclonal anti-p53 antibody was purchased from Santa Cruz Biotech. Monoclonal anti-MDM2 antibodies 4B11 and 2A10 were described previously (Zeng *et al.*, 1999). Monoclonal anti-p21^{waf1/cip1} antibodies were purchased from Neomarker Biotech and Oncogene Science, respectively. We also obtained some anti-p21^{waf1/cip1} antibodies from Wafik S.el-Deiry (University of Pennsylvania). pCDNA3-HA-MDM2 and pCMV-p53 were previously described (Zeng *et al.*, 1999). pCEP4-p21^{waf1/cip1} was described (el-Deiry *et al.*, 1993). The MDM2 mutant plasmids were described previously (Chen *et al.*, 1993). pCDNA3-p19^{arf} was a gift from Yue Xiong (University of North Carolina) (Zhang *et al.*, 1998). The p21^{waf1/cip1} 6KR mutant was generously provided by Bruce E. Clurman (Fred Hutchinson Cancer Research Center) (Sheaff *et al.*, 2000). GST–p21^{waf1/cip1}N and GST–p21^{waf1/cip1}C were generously provided by Anindya Dutta (Harvard Medical School) (Chen *et al.*, 1995).

Transient transfection and WB analysis

H1299 cells, or p53^{-/-}/mdm2^{-/-} or p53^{-/-}/mdmx^{-/-} MEFs (60% confluence in a 60 mm plate) were transfected with pCEP4-p21^{waf1/cip1} (1 μ g) alone or together with pCDNA3-HA-MDM2 or deletion mutant MDM2 (see figure legends for the amount of plasmids used). At 48 h post-transfection, cells were harvested for preparation of whole-cell lysates. Whole-cell lysates containing 50 or 100 μ g of protein were loaded directly onto an SDS-gel and proteins were detected by enhanced chemiluminescence (ECL) reagents (Bio-Rad) after WB using antibodies, as indicated in the figure legends.

NB analysis

NB analysis was conducted as described (Zeng *et al.*, 1999). Total RNA was isolated from transfected H1299 cells using the Trizol reagent (Life Technologies, Inc.). A 15 μ g aliquot of RNA was loaded onto a 1.5% agarose gel and transferred to a nitrocellulose membrane. The membrane after UV cross-linking was incubated with ³²P-labeled cDNA probes encoding human p21^{waf1/cip1} at 42°C overnight. After washing with 4 $\times$ SSC once and 1 $\times$ SSC twice, the blot was exposed to X-ray film overnight.

Analysis of p21^{waf1/cip1}'s half-life in cells

H1299 cells were transfected with the p21^{waf1/cip1} plasmid alone or together with the MDM2 or 1–441 MDM2 expression plasmid as described above. At 48 h after transfection, transiently transfected H1299 cells in 100 mm plates were labeled with 100 μ Ci/ml Easy Expression (PerkinElmer Life sciences) in 4 ml of Dulbecco's modified Eagle's medium (DMEM) with 2% dialyzed methionine-free calf serum for 45 min at 37°C. Cells were then washed with phosphate-buffered saline (PBS), incubated in DMEM containing 10% fetal bovine serum (FBS) and harvested at different time points. Cell lysates were prepared for IP as described above. The level of p21^{waf1/cip1} from the transfected cells was quantified by scanning the blot and using the Adobe Photoshop program, and plotted using the Cricket Graph (Figure 4A). These experiments were repeated twice.

In vivo ubiquitylation assay

The *in vivo* ubiquitylation assay was conducted as described previously (Xirodimas *et al.*, 2001). H1299 cells or p53^{-/-}/mdm2^{-/-} MEFs in 100 mm plates were transfected with His₆-ubiquitin (2 μ g), wild-type p21^{waf1/cip1} (2 μ g) or HA-MDM2 (2 μ g) expression plasmids using the lipofectAMINE reagent (Invitrogen). At 48 h after transfection, cells from each plate were harvested and split into two aliquots, one for straight WB and the other for detection of ubiquitylated proteins using Ni-NTA beads (Qiagen). The eluted proteins from the beads were analyzed by WB for polyubiquitylation of p21^{waf1/cip1} with monoclonal p21^{waf1/cip1} antibodies (NeoMarker, Ab11).

Immunofluorescent staining and fluorescent microscopic analysis

H1299 cells were co-transfected with the plasmid encoding p21^{waf1/cip1} alone, or together with the MDM2-, 1–441 MDM2 or Δ 150–230 MDM2 expression plasmids. At 48 h after transfection, cells were fixed for immunofluorescent staining with monoclonal anti-p21^{waf1/cip1} antibodies and polyclonal anti-MDM2 antibodies, as well as for DNA staining with 4',6-diamidino-2-penyindole (DAPI). The Alexa Fluor 488 (green) goat

anti-mouse antibody and the Alexa Fluor 546 (red) goat anti-rabbit antibody (Molecular Probes, OR) were used for p21^{waf1/cip1} and MDM2, respectively. Stained cells were analyzed under an Zeiss Axiovert 25 fluorescent microscope.

GST fusion protein association assay

The fusion proteins were expressed in *Escherichia coli* and purified on a glutathione–Sepharose 12B column. Protein–protein association assays were conducted as reported using fusion protein-containing beads (Zeng *et al.*, 1999). Purified p21^{waf1/cip1} was incubated with the glutathione–Sepharose 4B beads (50% slurry) containing ~500 ng of GST–MDM2, its deletion mutants as shown in Figure 4B, or GST, respectively. For a reverse GST pull-down assay, GST–p21^{waf1/cip1}, GST–p21^{waf1/cip1}N, GST–p21^{waf1/cip1}C and purified MDM2 were used. At 1 h after incubation at room temperature, the mixtures were washed intensively. Bound proteins were analyzed on a 12% SDS–gel and detected by WB.

FACS analysis

H1299 cells were transfected with an empty plasmid or the p21^{waf1/cip1} plasmid or with p21^{waf1/cip1} and MDM2. At 40 h post-transfection and 16 h after nocodazole treatment (0.4 μ M), cells were harvested and resuspended in 100 μ l of PBS, and transferred to a polystyrene tube. Into the tube, 200 μ l of pH 7.2 propidium iodide (PI) stain (50 μ l/ml PI, 30 μ g/ml polyethylene glycol 8000, 2 μ g/ml RNase A, 0.1% Triton X-100, 0.38 M NaCl) was added. Samples were incubated for 10 min and analyzed for DNA content using a Becton Dickinson FACScan flow cytometer. Data were analyzed by the multicycle software program using the polynomial S-phase algorithm.

RT-PCR analysis

Total RNA was isolated using TRIzol reagent (Invitrogen Corp, Carlsbad, CA) from p53^{−/−} and p53^{−/−}/mdm2^{−/−} MEFs after being treated or not with MG132. RT-PCRs were conducted as previously described (Zeng *et al.*, 2002). PCR products were analyzed on a 4.5% polyacrylamide gel followed by autoradiography, or on an agarose gel followed by ethidium bromide staining. The following primers were used: human p21^{waf1/cip1}, 5′-ATGTGAGAACCGGCTGGGGATG-3′, 5′-TTAGGGCTTCCTTGGAGAAG-3′; human GAPDH, 5′-TCTAGACGGCAGGTCTCAGGTCC-ACC-3′, 5′-CCACCCATGGCAAATTCATGGCA-3′; mouse p21^{waf1/cip1}, 5′-ATGTCCAATCCTGGTGATGTC-3′, 5′-TCAGGGTTTCTCTTG-CAGAAG-3′; mouse GAPDH, 5′-ATGGAGAAGG-CCGGG-GCCCA-CTT-3′, 5′-TTACTCCTTGGAGGCCATGTA-3′.

siRNA design and transfection

A twenty-one nucleotide RNA targeting human MDM2 mRNA 5′-AAG CCA UUG CUU UUG AAG UUA-3′ and a scrambled small RNA were chemically synthesized and supplied in the 2′-deprotected, annealed and desalted form by Dharmacon (Lafayette, CO). The sequence of the siRNA duplex was designed according to the manufacturer's recommendations and subjected to a BLAST search against the human genome sequence to ensure that endogenous non-mdm2 genes of the genome were targeted.

H1299 cells were split 16 h before transfection at 70% confluency. Oligofectamine (Invitrogen)-mediated transient transfection of siRNA was performed in 60 mm plates. siRNA (100 or 300 nM) and 9 μ l of oligofectamine were used for each plate in serum-free DMEM. Cells were incubated in transfection mixture for 5 h and further cultured in DMEM containing 10% FBS. The second siRNA transfection was carried out on the next day. Scrambled siRNAs were used as a control.

Acknowledgements

We thank David M.Keller and Jayme Gallegos for proofreading this manuscript. We also thank Guilliniao Lozano, Wafik S.el-Deiry, Jiandong Chen, Charles J.Sherr, Yue Xiong, Bruce E.Clurman and Anindya Dutta for generously providing us with cell lines, antibodies and plasmids. This work is supported by grants to H.L. from the NIH (CA095441, CA93614 and CA079721).

References

Appella,E. and Anderson,C.W. (2001) Post-translational modifications and activation of p53 by genotoxic stresses. *Eur. J. Biochem.*, **268**, 2764–2772.

Barak,Y., Juven,T., Haffner,R. and Oren,M. (1993) mdm2 expression is induced by wild type p53 activity. *EMBO J.*, **12**, 461–468.

Blagosklonny,M.V., Wu,G.S., Omura,S. and el-Deiry,W.S. (1996) Proteasome-dependent regulation of p21WAF1/CIP1 expression. *Biochem. Biophys. Res. Commun.*, **227**, 564–569.

Bunz,F., Dutriaux,A., Lengauer,C., Waldman,T., Zhou,S., Brown,J.P., Sedivy,J.M., Kinzler,K.W. and Vogelstein,B. (1998) Requirement for p53 and p21 to sustain G₂ arrest after DNA damage. *Science*, **282**, 1497–1501.

Calabro,V., Mansueto,G., Parisi,T., Vivo,M., Calogero,R.A. and La Mantia,G. (2002) The human MDM2 oncoprotein increases the transcriptional activity and the protein level of the p53 homolog p63. *J. Biol. Chem.*, **277**, 2674–2681.

Canman,C.E., Lim,D.S., Cimprich,K.A., Taya,Y., Tamai,K., Sakaguchi,K., Appella,E., Kastan,M.B. and Siliciano,J.D. (1998) Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. *Science*, **281**, 1677–1679.

Chen,J., Marechal,V. and Levine,A.J. (1993) Mapping of the p53 and mdm-2 interaction domains. *Mol. Cell. Biol.*, **13**, 4107–4114.

Chen,J., Jackson,P.K., Kirschner,M.W. and Dutta,A. (1995) Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA. *Nature*, **374**, 386–388.

Clark,P.A., Llanos,S. and Peters,G. (2002) Multiple interacting domains contribute to p14ARF mediated inhibition of MDM2. *Oncogene*, **21**, 4498–4507.

Crook,T., Marston,N.J., Sara,E.A. and Vousden,K.H. (1994) Transcriptional activation by p53 correlates with suppression of growth but not transformation. *Cell*, **79**, 817–827.

Datto,M.B., Li,Y., Panus,J.F., Howe,D.J., Xiong,Y. and Wang,X.F. (1995) Transforming growth factor β induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. *Proc. Natl Acad. Sci. USA*, **92**, 5545–5549.

David,D.C., Layfield,R., Serpell,L., Narain,Y., Goedert,M. and Spillantini,M.G. (2002) Proteasomal degradation of tau protein. *J. Neurochem.*, **83**, 176–185.

deStanchina,E. *et al.* (1998) E1A signaling to p53 involves the p19(ARF) tumor suppressor. *Genes Dev.*, **12**, 2434–2442.

el-Deiry,W.S. *et al.* (1993) WAF1, a potential mediator of p53 tumor suppression. *Cell*, **75**, 817–825.

Fang,S., Jensen,J.P., Ludwig,R.L., Vousden,K.H. and Weissman,A.M. (2000) Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. *J. Biol. Chem.*, **275**, 8945–8951.

Freedman,D.A. and Levine,A.J. (1998) Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. *Mol. Cell. Biol.*, **18**, 7288–7293.

Fuchs,S.Y., Adler,V., Buschmann,T., Wu,X. and Ronai,Z. (1998) Mdm2 association with p53 targets its ubiquitination. *Oncogene*, **17**, 2543–2547.

Fukuchi,K., Maruyama,H., Takagi,Y. and Gomi,K. (1999) Direct proteasome inhibition by clasto-lactacystin β -lactone permits the detection of ubiquitinated p21(waf1) in ML-1 cells. *Biochim. Biophys. Acta*, **1451**, 206–210.

Giaccia,A.J. and Kastan,M.B. (1998) The complexity of p53 modulation: emerging patterns from divergent signals. *Genes Dev.*, **12**, 2973–2983.

Gu,W. and Roeder,R.G. (1997) Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. *Cell*, **90**, 595–606.

Harper,J.W., Adami,G.R., Wei,N., Keyomarsi,K. and Elledge,S.J. (1993) The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G₁ cyclin-dependent kinases. *Cell*, **75**, 805–816.

Haupt,Y., Maya,R., Kazaz,A. and Oren,M. (1997) Mdm2 promotes the rapid degradation of p53. *Nature*, **387**, 296–299.

Honda,R. and Yasuda,H. (1999) Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. *EMBO J.*, **18**, 22–27.

Honda,R., Tanaka,H. and Yasuda,H. (1997) Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. *FEBS Lett.*, **420**, 25–27.

Hoyt,M.A., Zhang,M. and Coffino,P. (2003) Ubiquitin-independent mechanisms of mouse ornithine decarboxylase degradation are conserved between mammalian and fungal cells. *J. Biol. Chem.*, **278**, 12135–12143.

Kamijo,T., Weber,J.D., Zambetti,G., Zindy,F., Roussel,M.F. and Sherr,C.J. (1998) Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. *Proc. Natl Acad. Sci. USA*, **95**, 8292–8297.

Keller,D.M. *et al.* (2001) A DNA damage-induced p53 serine 392 kinase complex contains CK2, hSpt16 and SSRP1. *Mol. Cell*, **7**, 283–292.

- Kubbutat, M.H., Jones, S.N. and Vousden, K.H. (1997) Regulation of p53 stability by Mdm2. *Nature*, **387**, 299–303.
- Llanos, S., Clark, P.A., Rowe, J. and Peters, G. (2001) Stabilization of p53 by p14ARF without relocation of MDM2 to the nucleolus. *Nature Cell Biol.*, **3**, 445–452.
- Maki, C.G. and Howley, P.M. (1997) Ubiquitination of p53 and p21 is differentially affected by ionizing and UV radiation. *Mol. Cell. Biol.*, **17**, 355–363.
- Michael, D. and Oren, M. (2003) The p53–Mdm2 module and the ubiquitin system. *Semin. Cancer Biol.*, **13**, 49–58.
- Migliorini, D., Denchi, E.L., Danovi, D., Jochemsen, A., Capillo, M., Gobbi, A., Helin, K., Pelicci, P.G. and Marine, J.C. (2002) Mdm4 (Mdmx) regulates p53-induced growth arrest and neuronal cell death during early embryonic mouse development. *Mol. Cell. Biol.*, **22**, 5527–5538.
- Momand, J., Zambetti, G.P., Olson, D.C., George, D. and Levine, A.J. (1992) The *mdm-2* oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. *Cell*, **69**, 1237–1245.
- Nakanishi, Y. *et al.* (2000) Polycyclic aromatic hydrocarbon carcinogens increase ubiquitination of p21 protein after the stabilization of p53 and the expression of p21. *Am. J. Respir. Cell. Mol. Biol.*, **22**, 747–754.
- Orlowski, M. and Wilk, S. (2003) Ubiquitin-independent proteolytic functions of the proteasome. *Arch. Biochem. Biophys.*, **415**, 1–5.
- Parant, J., Chaves-Reyes, A., Little, N.A., Yan, W., Reinke, V., Jochemsen, A.G. and Lozano, G. (2001) Rescue of embryonic lethality in *Mdm4*-null mice by loss of Trp53 suggests a novoverlapping pathway with MDM2 to regulate p53. *Nature Genet.*, **29**, 92–95.
- Sheaff, R.J., Singer, J.D., Swanger, J., Smitherman, M., Roberts, J.M. and Clurman, B.E. (2000) Proteasomal turnover of p21Cip1 does not require p21Cip1 ubiquitination. *Mol. Cell*, **5**, 403–410.
- Shieh, S.Y., Ikeda, M., Taya, Y. and Prives, C. (1997) DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. *Cell*, **91**, 325–334.
- Sun, P., Dong, P., Dai, K., Hannon, G.J. and Beach, D. (1998) p53-independent role of MDM2 in TGF- β 1 resistance. *Science*, **282**, 2270–2272.
- Tao, W. and Levine, A.J. (1999) P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. *Proc. Natl Acad. Sci. USA*, **96**, 6937–6941.
- Toutou, R., Richardson, J., Bose, S., Nakanishi, M., Rivett, J. and Allday, M.J. (2001) A degradation signal located in the C-terminus of p21WAF1/CIP1 is a binding site for the C8 α -subunit of the 20S proteasome. *EMBO J.*, **20**, 2367–2375.
- Verma, R. and Deshaies, R.J. (2000) A proteasome howdunit: the case of the missing signal. *Cell*, **101**, 341–344.
- Vogelstein, B., Lane, D. and Levine, A.J. (2000) Surfing the p53 network. *Nature*, **408**, 307–310.
- Weber, J.D., Taylor, L.J., Roussel, M.F., Sherr, C.J. and Bar-Sagi, D. (1999) Nucleolar Arf sequesters Mdm2 and activates p53. *Nature Cell Biol.*, **1**, 20–26.
- Weber, J.D., Kuo, M.L., Bothner, B., DiGiammarino, E.L., Kriwacki, R.W., Roussel, M.F. and Sherr, C.J. (2000) Cooperative signals governing ARF–mdm2 interaction and nucleolar localization of the complex. *Mol. Cell. Biol.*, **20**, 2517–2528.
- Wu, X., Bayle, J.H., Olson, D. and Levine, A.J. (1993) The p53–mdm-2 autoregulatory feedback loop. *Genes Dev.*, **7**, 1126–1132.
- Xiao, Z.X., Chen, J., Levine, A.J., Modjtahedi, N., Xing, J., Sellers, W.R. and Livingston, D.M. (1995) Interaction between the retinoblastoma protein and the oncoprotein MDM2. *Nature*, **373**, 694–698.
- Xirodimas, D., Saville, M.K., Edling, C., Lane, D.P. and Lain, S. (2001) Different effects of p14ARF on the levels of ubiquitinated p53 and Mdm2 *in vivo*. *Oncogene*, **20**, 4972–4983.
- Xie, Y. and Varshavsky, A. (2000) Physical association of ubiquitin ligases and the 26S proteasome. *Proc. Natl Acad. Sci. USA*, **97**, 2497–2502.
- Yu, Z.K., Geyer, R.K. and Maki, C.G. (2000) MDM2-dependent ubiquitination of nuclear and cytoplasmic p53. *Oncogene*, **19**, 5892–5897.
- Zeng, S.X., Dai, M.S., Keller, D.M. and Lu, H. (2002) SSRP1 functions as a co-activator of the transcriptional activator p63. *EMBO J.*, **21**, 5487–5497.
- Zeng, X. *et al.* (1999) MDM2 suppresses p73 function without promoting p73 degradation. *Mol. Cell. Biol.*, **19**, 3257–3266.
- Zhang, Y., Xiong, Y. and Yarbrough, W.G. (1998) ARF promotes MDM2 degradation and stabilizes p53: ARF–INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. *Cell*, **92**, 725–734.
- Zindy, F., Eischen, C.M., Randle, D.H., Kamijo, T., Cleveland, J.L., Sherr, C.J. and Roussel, M.F. (1998) Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. *Genes Dev.*, **12**, 2424–2433.

Received June 30, 2003; revised October 10, 2003;
accepted October 13, 2003